Navigating Anthem (Elevance Health) Aimovig Prior Authorization

Successfully managing **Anthem (Elevance Health) Aimovig prior authorization** requires precision across specific submission channels and adherence to payer-specific clinical criteria. Klivira streamlines this complex process for CGRP receptor antagonists like erenumab.

Revenue cycle directors and prior authorization coordinators face unique challenges with specialty medications under managed care. For preventive migraine therapies such as Aimovig, understanding the exact requirements of Anthem-licensed plans is critical to minimize denials and accelerate patient access. This guide outlines the operational specifics for erenumab within the Elevance Health ecosystem.

Aimovig (Erenumab) Clinical Overview for Anthem PA

Aimovig (erenumab) is a CGRP receptor antagonist indicated for the preventive treatment of migraine, including both chronic and episodic forms. As a specialty medication, it is typically subject to rigorous utilization management by Anthem-licensed plans. Step therapy, often requiring trial and failure of generic preventive migraine therapies, is a common prerequisite for approval.

Anthem's Prior Authorization Channels for Aimovig

For Anthem-licensed plans, Aimovig, as a self-administered subcutaneous injection, typically falls under the pharmacy benefit. Prior authorization for these medications is primarily managed through CarelonRx, Elevance Health's in-house PBM. Providers can submit pharmacy benefit prior authorizations via the CarelonRx provider system or through integrated electronic prior authorization (ePA) platforms.

Key Submission Pathways for Aimovig PA with Anthem

CarelonRx provider portal for direct submission of pharmacy benefit prior authorizations.
CoverMyMeds and Surescripts ePA platforms, which integrate with CarelonRx for prescriber-initiated workflows.
Availity Essentials serves as Anthem's primary multi-payer provider workspace for general inquiries, member benefit lookup, and document upload, though direct pharmacy PA routing is via CarelonRx or ePA partners.
X12 278 transactions are supported by Anthem for medical benefit prior authorizations, though less common for self-administered pharmacy benefit drugs like Aimovig.

Understanding Anthem's Utilization Management Criteria for Erenumab

Anthem operating companies publish their medical-policy and clinical-UM-guideline libraries through provider sites, accessible via Availity. For pharmacy benefit drugs like Aimovig, CarelonRx maintains specific formulary and prior authorization criteria, which typically include clinical indications, step therapy requirements, and quantity limits. It is crucial to consult the specific policy number, plan-state context, and effective date for the most accurate requirements.

Common Denial Reasons and Appeal Pathways for Aimovig with Anthem

Common denial categories for Aimovig prior authorizations with Anthem often include 'step therapy not completed,' 'medical necessity / insufficient documentation,' and 'non-formulary pharmacy denials.' Denials are typically communicated via X12 277/835 transactions or Availity status updates. Appeals for standard medical and pharmacy prior authorizations route through the Anthem operating-company appeals process, which includes options for peer-to-peer reviews.

Electronic Prior Authorization (ePA) and Da Vinci Initiatives

Elevance Health, through its Anthem operating companies, has actively participated in Da Vinci Project initiatives, including efforts related to Prior Authorization Support (PAS), Coverage Requirements Discovery (CRD), and Documentation Templates and Rules (DTR). For pharmacy benefit drugs like Aimovig, electronic prior authorization (ePA) is widely supported via established platforms such as CoverMyMeds and Surescripts, integrating with CarelonRx workflows.

Frequently asked questions

Is Aimovig typically a medical or pharmacy benefit drug with Anthem?

Aimovig (erenumab), as a self-administered subcutaneous injection, is typically covered under the pharmacy benefit by Anthem-licensed plans. Prior authorization for Aimovig will generally route through CarelonRx, Elevance Health's pharmacy benefit manager.

What are the common step therapy requirements for Aimovig under Anthem plans?

Anthem-licensed plans commonly require step therapy for Aimovig, often mandating a trial and failure of other generic or preferred preventive migraine therapies before approval for erenumab. Specific requirements are detailed in the CarelonRx formulary and prior authorization criteria.

How can I access Anthem's clinical criteria for Aimovig?

Clinical criteria for Aimovig under Anthem-licensed plans are primarily found within the CarelonRx formulary and prior authorization guidelines. These can typically be accessed through the CarelonRx provider portal or through the Anthem provider sites via Availity for general medical policies.

Which ePA platforms does Anthem support for Aimovig?

For pharmacy benefit drugs like Aimovig, Anthem (via CarelonRx) supports electronic prior authorization (ePA) submissions through industry-standard platforms such as CoverMyMeds and Surescripts. These platforms facilitate efficient digital submission of PA requests.

What should I do if an Aimovig PA is denied by Anthem?

If an Aimovig prior authorization is denied by an Anthem-licensed plan, review the specific denial reason provided. Common next steps include submitting an appeal through the Anthem operating company's documented appeals process, providing additional clinical documentation, or initiating a peer-to-peer review with an Anthem medical director.

Does Carelon Medical Benefits Management handle Aimovig prior authorizations for Anthem?

No, Carelon Medical Benefits Management (formerly AIM Specialty Health) typically manages prior authorizations for specific domains like advanced imaging, cardiology, and musculoskeletal services. Aimovig, as a pharmacy benefit drug, falls under the purview of CarelonRx for prior authorization with Anthem-licensed plans.